Huvers F C, De Leeuw P W, Houben A J, De Haan C H, Hamulyak K, Schouten H, Wolffenbuttel B H, Schaper N C
Department of General Internal Medicine, University Hospital Nijmegen, The Netherlands.
Diabetes. 1999 Jun;48(6):1300-7. doi: 10.2337/diabetes.48.6.1300.
It is unknown whether and to what extent changes in various endothelial functions and adrenergic responsiveness are related to the development of microvascular complications in type 1 diabetes. Therefore, endothelium-dependent and endothelium-independent vasodilatation, endothelium-dependent hemostatic factors, and one and two adrenergic vasoconstrictor responses were determined in type 1 patients with and without microvascular complications. A total of 34 patients with type 1 diabetes were studied under euglycemic conditions on two occasions (11 without microangiopathy, 10 with proliferative and preproliferative retinopathy previously treated by laser coagulation, 13 with microalbuminuria, and 12 healthy volunteers also were studied). Forearm vascular responses to brachial artery infusions of N(G)-monomethyl-L-arginine (L-NMMA), sodium nitroprusside, acetylcholine (ACh), clonidine, and phenylephrine were determined. The ACh infusions were repeated during coinfusion of L-arginine. Furthermore, plasminogen activator inhibitor type 1 (PAI-1) activity, tissue plasminogen activator antigen levels, von Willebrand factor antigen levels, tissue factor pathway inhibitor (TFPI) activity, and endothelin-1 levels were measured. No differences in endothelium-dependent or endothelium-independent vasodilatation or adrenergic constriction were observed between the diabetic patients and the healthy volunteers. In comparison to the first ACh infusion, the maximal response to repeated ACh during L-arginine administration was reduced in the diabetic patients, except in the patients with proliferative and preproliferative retinopathy previously treated by laser coagulation. In these patients, the combined infusion of L-arginine and ACh resulted in an enhanced response. TFPI activity was elevated, and PAI-1 activity was reduced in the type 1 diabetic patients. Furthermore, PAI-1 activity was positively correlated with urinary albumin excretion (r = 0.48, P < 0.01) and inversely correlated with the vasodilatory response to the highest ACh dose (r = -0.37, P < 0.05). The response to the highest ACh and L-NMMA dose were positively correlated with mean arterial blood pressure (r = 0.32, P < 0.01; r = 0.41, P < 0.01, respectively). Forearm endothelium-dependent and endothelium-independent vasodilatation and adrenergic responsiveness were unaltered in type 1 diabetic patients with and without microvascular complications. Relative to healthy control subjects, endothelium-dependent vasodilatation was depressed during a repeated ACh challenge (with L-arginine coinfusion) in the diabetic patients without complications or with microalbuminuria. In contrast, this vasodilatation was enhanced in the patients with retinopathy. Elevation of TFPI was the most consistent marker of endothelial damage of all the endothelial markers measured.
1型糖尿病中各种内皮功能和肾上腺素能反应性的变化是否以及在何种程度上与微血管并发症的发生相关尚不清楚。因此,我们测定了有和无微血管并发症的1型糖尿病患者的内皮依赖性和非内皮依赖性血管舒张、内皮依赖性止血因子以及一级和二级肾上腺素能血管收缩反应。总共34例1型糖尿病患者在血糖正常的情况下接受了两次研究(11例无微血管病变,10例曾接受激光凝固治疗的增殖性和增殖前期视网膜病变患者,13例微量白蛋白尿患者,并且还研究了12名健康志愿者)。测定了前臂血管对肱动脉输注N(G)-单甲基-L-精氨酸(L-NMMA)、硝普钠、乙酰胆碱(ACh)、可乐定和去氧肾上腺素的反应。在输注L-精氨酸的同时重复输注ACh。此外,还测量了纤溶酶原激活物抑制剂1型(PAI-1)活性、组织纤溶酶原激活物抗原水平、血管性血友病因子抗原水平、组织因子途径抑制剂(TFPI)活性和内皮素-1水平。糖尿病患者和健康志愿者之间在内皮依赖性或非内皮依赖性血管舒张或肾上腺素能收缩方面未观察到差异。与首次输注ACh相比,除了曾接受激光凝固治疗的增殖性和增殖前期视网膜病变患者外,糖尿病患者在输注L-精氨酸期间重复输注ACh时的最大反应降低。在这些患者中,L-精氨酸和ACh联合输注导致反应增强。1型糖尿病患者的TFPI活性升高,PAI-1活性降低。此外,PAI-1活性与尿白蛋白排泄呈正相关(r = 0.48,P < 0.01),与对最高ACh剂量的血管舒张反应呈负相关(r = -0.37,P < 0.05)。对最高ACh和L-NMMA剂量的反应与平均动脉血压呈正相关(分别为r = 0.32,P < 0.01;r = 0.41,P < 0.01)。有和无微血管并发症的1型糖尿病患者的前臂内皮依赖性和非内皮依赖性血管舒张以及肾上腺素能反应性未改变。与健康对照受试者相比,无并发症或有微量白蛋白尿的糖尿病患者在重复ACh激发试验(同时输注L-精氨酸)期间内皮依赖性血管舒张受到抑制。相反,视网膜病变患者的这种血管舒张增强。在所有测量的内皮标志物中,TFPI升高是内皮损伤最一致的标志物。